Weight-Loss Wonder or Market Bomb? Eli Lilly's Tirzepatide Sends Sleep Apnea Device Stocks Plunging

According to the Zhisheng Finance APP, Eli Lilly and Company (LLY.US) sells under the Mounjaro and Zepbound brands.The new weight-loss drug tirzepatide, whichRecent clinical trial results have not only caused a sensation in the medical community but also stirred waves in the stock market. This drug has demonstrated remarkable efficacy in weight loss and diabetes treatment, and the latest research indicates that it can significantly alleviate obstructive sleep apnea symptoms in obese patients. This discovery undoubtedly represents a historic breakthrough in the fields of obesity and sleep apnea treatment. However, this medical breakthrough has dealt a severe blow to the stock prices of related medical device manufacturers.

For example, the share price of ResMed (RMD.US), a ventilator manufacturer, fell by about 11% on Monday, marking the largest single-day drop in more than 10 months. The share price of Inspire Medical Systems (INSP.US), a manufacturer of sleep apnea implants, plummeted by 17%, hitting its lowest point since November. AdaptHealth (AHCO.US), which sells sleep therapy products, also suffered, with its share price dropping by 8.1%, the largest decline since December.

This phenomenon is quite similar to the stock market turmoil a year ago, when diabetes device manufacturers such as Insulet (PODD.US) and Tandem Diabetes Care (TNDM.US) Plunged due to concerns over the rise of GLP-1 drugs. In 2023, Insulet's stock price fell by about 26%, while Tandem Diabetes Care plummeted by 34%.

Market analysts have conducted an in-depth analysis of this phenomenon. Analysts at Citigroup downgraded ResMed from "Buy" to "Neutral" and pointed out that as the efficacy of tirzepatide gradually gains recognition, some patients with mild conditions may choose to forgo traditional CPAP therapy. Meanwhile, Richard Newitter, an analyst at Truist Securities, expressed optimism about Eli Lilly's prospects, stating that although the stock price might experience short-term fluctuations, its weight-loss business still holds potential in the long run.

According to reports, the preliminary trial results of tirzepatide announced by Eli Lilly and Company in April have already drawn significant attention from investors, who are now looking forward to the full details of the study being released so they can better assess its potential impact on the market.

Stifel analyst Jonathan D. Block noted in a report that the new data added more uncertainty for device manufacturers, but he emphasized that the "impressive results" of tirzepatide could lead to GLP-1 drugs playing a more critical role in treatment paradigms.

The research achievements of tirzepatide not only provide new hope for the treatment of obesity and related diseases but also have a profound impact on the medical device market. With further research and increased market awareness, this drug will play an even more significant role in the future.